The University Clinic for Children’s Diseases said that Kaftrio therapy in combination with Kalydeco (known as Tricafta in the U.S.) began to be given 1 month ago to 8 patients, and as of yesterday also to 4 more patients with cystic fibrosis at this clinic and the Pulmonology Clinic. Therapy is indicated in patients with cystic fibrosis who are 6 years of age and older and have at least one F508del mutation in the genotype.
“In conditions where therapy is not provided for all patients suffering from cystic fibrosis who meet the criteria for it (around 80), we give preference for therapy to patients with worse lung function expressed through FEV1,” said the Clinic.
